Return to The CPNP Perspective issue main page.< Previous Article  Next Article >

Major depressive disorder (MDD) is becoming one of the most prevalent and proliferating public health concerns worldwide because of its high rate of morbidity, recurrence, and associated suicide, all of which result in a profound burden to both the individual and society. Clinical pharmacists face the everyday challenge of providing individualized, safe, and effective care for patients with MDD.

Through two interactive modules, this activity will review recent clinical data and guidelines in the management of MDD. Case studies will introduce potential treatment strategies, communication tools, and other data for learners to consider. This complimentary, application-based course consists of two modules (each valued at 1.0 contact hours of ACPE credit) authored by psychiatric pharmacists on the following topics:

Module 1: The Pathogenesis of Depression: From Traditional Theories to Novel Concepts (Matthew Fuller, PharmD, BCPS, BCPP, FASHP and Roger Sommi, PharmD, FCCP, BCPP)

Learning Objectives

  1. Examine the monoamine hypotheses of depression.
  2. Apply current theories on the role of serotonin and its varying receptor profiles to an understanding of the dysregulation of mood, cognition, and behavior.
  3. Utilize an understanding of the neurobiology of depression to examine clinical updates on current and novel treatment paradigms in depression.
  4. Interpret recent clinical trial data implicating the concomitant modulation of several serotonergic receptor systems in optimizing therapeutic outcomes in MDD.

Module 2: Treatment Selection in Depression: The Role of Pharmacists in Optimizing Therapeutic Outcomes (Patrick Finley, PharmD, BCPP and Amy Werremeyer, PharmD, BCPP)

Learning Objectives

  1. Modify treatment plans for MDD by taking into account the benefits/limitations of traditional antidepressants in achieving symptomatic remission and recovery.
  2. Demonstrate the evidence-based need for emerging therapies with novel mechanisms of action in targeting residual symptoms in depression management.
  3. Apply an understanding of the importance of symptomatic remission and recovery in achieving optimal outcomes in depression management.
  4. Illustrate the limitations of current health system management of depression and the evolving role of the clinical pharmacists in optimizing outcomes.

There is no fee for the activity and participants must successfully complete an exam and evaluation at the end of each module in order to receive 2.0 contact hours (0.20 CEUs) of continuing pharmacy education credit. Take advantage of this great opportunity now!

Return to The CPNP Perspective issue main page.< Previous Article  Next Article >